Back to today’s briefing

Story perspectives

Sarepta Defies FDA, Challenges Drug Sales Authority

7/21/2025

43 5

Summary

Story summary

In a bold move, Sarepta has defied the FDA's request to halt sales of its drug, challenging the agency's authority. While the FDA can eventually withdraw drugs, the lengthy process means Sarepta's stance could reshape industry norms, highlighting a growing tension between regulatory bodies and pharmaceutical companies.

1 of 1

Story summary

In a bold move, Sarepta has defied the FDA's request to halt sales of its drug, challenging the agency's authority. While the FDA can eventually withdraw drugs, the lengthy process means Sarepta's stance could reshape industry norms, highlighting a growing tension between regulatory bodies and pharmaceutical companies.